|
1
|
Taylor DC, Falconer MA, Bruton CJ and
Corsellis JAN: Focal dysplasia of the cerebral cortex in epilepsy.
J Neurol Neurosurg Psychiatry. 34:369–387. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palmini A, Najm I, Avanzini G, Babb T,
Guerrini R, Foldvary-Schaefer N, Jackson G, Lüders HO, Prayson R,
Spreafico R, et al: Terminology and classification of the cortical
dysplasias. Neurology. 62(Suppl 3): S2–S8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartman AL, Santos P, Dolce A and Hardwick
JM: The mTOR inhibitor rapamycin has limited acute anticonvulsant
effects in mice. PLoS One. 7:e451562012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meikle L, Pollizzi K, Egnor A, Kramvis I,
Lane H, Sahin M and Kwiatkowski DJ: Response of a neuronal model of
tuberous sclerosis to mammalian target of rapamycin (mTOR)
inhibitors: Effects on mTORC1 and Akt signaling lead to improved
survival and function. J Neurosci. 28:5422–5432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stafstrom CE and Rho JM: The ketogenic
diet as a treatment paradigm for diverse neurological disorders.
Front Pharmacol. 3:592012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barkovich AJ and Kuzniecky RI:
Neuroimaging of focal malformations of cortical development. J Clin
Neurophysiol. 13:481–494. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barkovich AJ, Kuzniecky RI, Jackson GD,
Guerrini R and Dobyns WB: A developmental and genetic
classification for malformations of cortical development.
Neurology. 65:1873–1887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tassi L, Colombo N, Garbelli R, Francione
S, Lo Russo G, Mai R, Cardinale F, Cossu M, Ferrario A, Galli C, et
al: Focal cortical dysplasia: Neuropathological subtypes, EEG,
neuroimaging and surgical outcome. Brain. 125:1719–1732. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diehl B, Najm I, LaPresto E, Prayson R,
Ruggieri P, Mohamed A, Ying Z, Lieber M, Babb T, Bingaman W, et al:
Temporal lobe volumes in patients with hippocampal sclerosis with
or without cortical dysplasia. Neurology. 62:1729–1735. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blümcke I, Thom M, Aronica E, Armstrong
DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ,
Battaglia G, et al: The clinicopathologic spectrum of focal
cortical dysplasias: A consensus classification proposed by an ad
hoc Task Force of the ILAE Diagnostic Methods Commission.
Epilepsia. 52:158–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kwan P and Brodie MJ: Refractory epilepsy:
Mechanisms and solutions. Expert Rev Neurother. 6:397–406. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng LH, Rensing NR and Wong M: The
mammalian target of rapamycin signaling pathway mediates
epileptogenesis in a model of temporal lobe epilepsy. J Neurosci.
29:6964–6972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Vliet EA, Forte G, Holtman L, den
Burger JC, Sinjewel A, de Vries HE, Aronica E and Gorter JA:
Inhibition of mammalian target of rapamycin reduces epileptogenesis
and blood-brain barrier leakage but not microglia activation.
Epilepsia. 53:1254–1263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penry JK and Dean JC: Prevention of
intractable partial seizures by intermittent vagal stimulation in
humans: Preliminary results. Epilepsia. 31(Suppl 2): S40–S43. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ben-Menachem E: Vagus-nerve stimulation
for the treatment of epilepsy. Lancet Neurol. 1:477–482. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DeGiorgio CM, Schachter SC, Handforth A,
Salinsky M, Thompson J, Uthman B, Reed R, Collins S, Tecoma E,
Morris GL, et al: Prospective long-term study of vagus nerve
stimulation for the treatment of refractory seizures. Epilepsia.
41:1195–1200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holmes MD, Silbergeld DL, Drouhard D,
Wilensky AJ and Ojemann LM: Effect of vagus nerve stimulation on
adults with pharmacoresistant generalized epilepsy syndromes.
Seizure. 13:340–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang X, McMahon J, Yang J, Shin D and
Huang Y: Rapamycin down-regulates KCC2 expression and increases
seizure susceptibility to convulsants in immature rats.
Neuroscience. 219:33–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goto J, Talos DM, Klein P, Qin W, Chekaluk
YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA, et
al: Regulable neural progenitor-specific Tsc1 loss yields giant
cells with organellar dysfunction in a model of tuberous sclerosis
complex. Proc Natl Acad Sci USA. 108:E1070–E1079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng LH, Rensing NR, Zhang B, Gutmann DH,
Gambello MJ and Wong M: Tsc2 gene inactivation causes a more severe
epilepsy phenotype than Tsc1 inactivation in a mouse model of
tuberous sclerosis complex. Hum Mol Genet. 20:445–454. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carson RP, Van Nielen DL, Winzenburger PA
and Ess KC: Neuronal and glia abnormalities in Tsc1-deficient
forebrain and partial rescue by rapamycin. Neurobiol Dis.
45:369–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Way SW, Rozas NS, Wu HC, McKenna J III,
Reith RM, Hashmi SS, Dash PK and Gambello MJ: The differential
effects of prenatal and/or postnatal rapamycin on
neurodevelopmental defects and cognition in a neuroglial mouse
model of tuberous sclerosis complex. Hum Mol Genet. 21:3226–3236.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buckmaster PS and Lew FH: Rapamycin
suppresses mossy fiber sprouting but not seizure frequency in a
mouse model of temporal lobe epilepsy. J Neurosci. 31:2337–2347.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharma S, Gulati S, Kalra V, Agarwala A
and Kabra M: Seizure control and biochemical profile on the
ketogenic diet in young children with refractory epilepsy - Indian
experience. Seizure. 18:446–449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kossoff EH, Zupec-Kania BA and Rho JM:
Ketogenic diets: An update for child neurologists. J Child Neurol.
24:979–988. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suo C, Liao J, Lu X, Fang K, Hu Y, Chen L,
Cao D, Huang T, Li B and Li C: Efficacy and safety of the ketogenic
diet in Chinese children. Seizure. 22:174–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lefevre F and Aronson N: Ketogenic diet
for the treatment of refractory epilepsy in children: A systematic
review of efficacy. Pediatrics. 105:E462000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keene DL: A systematic review of the use
of the ketogenic diet in childhood epilepsy. Pediatr Neurol.
35:1–5. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neal EG, Chaffe H, Schwartz RH, Lawson MS,
Edwards N, Fitzsimmons G, Whitney A and Cross JH: The ketogenic
diet for the treatment of childhood epilepsy: A randomised
controlled trial. Lancet Neurol. 7:500–506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levy RG, Cooper PN and Giri P: Ketogenic
diet and other dietary treatments for epilepsy. Cochrane Database
Syst Rev. 3:CD0019032012.PubMed/NCBI
|
|
31
|
French JA, Kanner AM, Bautista J,
Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J,
Schachter SC, et al: Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology; Quality
Standards Subcommittee of the American Academy of Neurology;
American Epilepsy Society: Efficacy and tolerability of the new
antiepileptic drugs II: treatment of refractory epilepsy: report of
the Therapeutics and Technology Assessment Subcommittee and Quality
Standards Subcommittee of the American Academy of Neurology and the
American Epilepsy Society. Neurology. 62:1261–1273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Engel J Jr, Van Ness PC, Rasmussen TB and
Ojemann LM: Outcome with respect to epileptic seizures. Surgical
treatment of the epilepsies. Engel J Jr: Raven Press. (New York,
NY). 609–621. 1993.
|
|
33
|
Wada JA: Callosal bisection and
transcallosal secondary antiepileptogenesis. Epilepsia. 46(Suppl
1): 2–6. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Theodore WH and Fisher RS: Brain
stimulation for epilepsy. Lancet Neurol. 3:111–118. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spencer SS, Schramm J, Wyler A, O'Connor
M, Orbach D, Krauss G, Sperling M, Devinsky O, Elger C, Lesser R,
et al: Multiple subpial transection for intractable partial
epilepsy: an international meta-analysis. Epilepsia. 43:141–145.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Labar D: Vagus nerve stimulation for 1
year in 269 patients on unchanged antiepileptic drugs. Seizure.
13:392–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Janszky J, Hoppe M, Behne F, Tuxhorn I,
Pannek HW and Ebner A: Vagus nerve stimulation: Predictors of
seizure freedom. J Neurol Neurosurg Psychiatry. 76:384–389. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huf RL, Mamelak A and Kneedy-Cayem K:
Vagus nerve stimulation therapy: 2-year prospective open-label
study of 40 subjects with refractory epilepsy and low IQ who are
living in long-term care facilities. Epilepsy Behav. 6:417–423.
2005. View Article : Google Scholar : PubMed/NCBI
|
